Great Lakes Advisors LLC reduced its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 51.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 40,365 shares of the company’s stock after selling 43,349 shares during the quarter. Great Lakes Advisors LLC’s holdings in Neurocrine Biosciences were worth $3,806,000 as of its most recent filing with the SEC.
A number of other institutional investors have also made changes to their positions in NBIX. Norges Bank acquired a new stake in Neurocrine Biosciences in the 4th quarter valued at approximately $111,786,000. BlackRock Inc. grew its stake in shares of Neurocrine Biosciences by 6.6% in the first quarter. BlackRock Inc. now owns 13,466,650 shares of the company’s stock worth $1,363,094,000 after acquiring an additional 838,997 shares during the last quarter. Braidwell LP bought a new position in Neurocrine Biosciences during the first quarter worth $77,615,000. Armistice Capital LLC raised its stake in Neurocrine Biosciences by 76.9% during the 1st quarter. Armistice Capital LLC now owns 1,592,000 shares of the company’s stock valued at $161,142,000 after purchasing an additional 692,000 shares during the last quarter. Finally, Ieq Capital LLC bought a new stake in Neurocrine Biosciences in the 2nd quarter valued at $45,384,000. 93.54% of the stock is currently owned by institutional investors.
Neurocrine Biosciences Stock Up 0.4 %
Shares of NASDAQ NBIX opened at $109.43 on Tuesday. Neurocrine Biosciences, Inc. has a 12-month low of $89.04 and a 12-month high of $129.29. The firm’s 50-day simple moving average is $112.13 and its 200 day simple moving average is $103.78. The company has a market cap of $10.75 billion, a price-to-earnings ratio of 58.83, a price-to-earnings-growth ratio of 1.02 and a beta of 0.40.
Insider Buying and Selling at Neurocrine Biosciences
In other news, Director Gary A. Lyons sold 5,000 shares of the business’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $110.06, for a total transaction of $550,300.00. Following the completion of the sale, the director now owns 203,697 shares in the company, valued at $22,418,891.82. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, insider David W. Boyer sold 1,437 shares of the firm’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $112.68, for a total value of $161,921.16. Following the transaction, the insider now owns 4,894 shares of the company’s stock, valued at approximately $551,455.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gary A. Lyons sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $110.06, for a total transaction of $550,300.00. Following the sale, the director now directly owns 203,697 shares of the company’s stock, valued at $22,418,891.82. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 16,425 shares of company stock worth $1,826,659. Insiders own 4.40% of the company’s stock.
Analysts Set New Price Targets
A number of brokerages have recently commented on NBIX. Royal Bank of Canada cut their price objective on shares of Neurocrine Biosciences from $128.00 to $121.00 and set a “sector perform” rating for the company in a research report on Friday, November 10th. BMO Capital Markets reduced their price objective on Neurocrine Biosciences from $111.00 to $100.00 and set a “market perform” rating for the company in a research report on Friday, November 10th. Morgan Stanley restated an “overweight” rating and set a $130.00 price objective on shares of Neurocrine Biosciences in a research report on Wednesday, August 2nd. Jefferies Financial Group raised their target price on Neurocrine Biosciences to $123.00 in a research report on Monday, August 21st. Finally, StockNews.com lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 24th. Five research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $131.46.
Neurocrine Biosciences Profile
Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas.
- Five stocks we like better than Neurocrine Biosciences
- What Are Growth Stocks and Investing in Them
- Safeguard your portfolio with these three bargain stocks
- NYSE Stocks Give Investors a Variety of Quality Options
- Membership clubs gain leverage for the consumer rebound
- Airline Stocks – Top Airline Stocks to Buy Now
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.